Contact
searchSearch
HMP Global

Multiple Myeloma

Featured Article

News
Outpatient Cilta-Cel Administration May Reduce Health Care Utilization in RRMM
06/23/2026
Rebecca Amrick
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care...
06/23/2026
First Report Managed Care
News
Talquetamab Shows Lower Cost Per Response in Relapsed or Refractory Multiple Myeloma
06/16/2026
Lisa Kuhns, PhD, MD
Talquetamab delivered more than double the response rate of usual care while lowering the cost per responder, highlighting its potential economic and clinical value for heavily pretreated patients with relapsed or refractory multiple myeloma.
Talquetamab delivered more than double the response rate of usual care while lowering the cost per responder, highlighting its potential economic and clinical value for heavily pretreated patients with relapsed or refractory multiple myeloma.
Talquetamab delivered more than...
06/16/2026
First Report Managed Care
News
Pneumonia Hospitalizations Drive Rising Costs in Multiple Myeloma Care
06/08/2026
Grace Taylor, MS, MA
Pneumonia-related hospitalizations among patients with multiple myeloma are becoming increasingly costly despite declining mortality rates, highlighting persistent disparities and the urgent need for strategies to prevent serious infections...
Pneumonia-related hospitalizations among patients with multiple myeloma are becoming increasingly costly despite declining mortality rates, highlighting persistent disparities and the urgent need for strategies to prevent serious infections...
Pneumonia-related...
06/08/2026
First Report Managed Care
News
Linvoseltamab Demonstrates Lower Care Costs than Teclistamab and Elranatamab for TCE RRMM
05/26/2026
Rebecca Amrick
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower...
05/26/2026
First Report Managed Care
News
Linvoseltamab Demonstrates Improved Efficacy for Patients With TCE RRMM
05/14/2026
Rebecca Amrick
Linvoseltamab outperformed real-world treatment regimens for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM), with higher response rates and more durable outcomes in the LINKER-MM1 trial.
Linvoseltamab outperformed real-world treatment regimens for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM), with higher response rates and more durable outcomes in the LINKER-MM1 trial.
Linvoseltamab outperformed...
05/14/2026
First Report Managed Care
News
Teclistamab Shows Comparable Efficacy but Lower Costs Than Elranatamab in RRMM Study
05/04/2026
Rebecca Amrick
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but...
05/04/2026
First Report Managed Care
News
Real-World Elranatamab in RRMM Falls Short on Durability Despite Strong Initial Responses
04/17/2026
Rebecca Amrick
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising...
04/17/2026
First Report Managed Care
News
Outpatient Cilta-cel Shows Promise in Multiple Myeloma, With Early Signs of Lower Costs and Comparable Outcomes
04/09/2026
Rebecca Amrick
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review...
04/09/2026
First Report Managed Care
News
Higher Health Care Burden in Multiple Myeloma With Extramedullary Disease, Study Finds
12/02/2025
Grace Taylor, MS, MA
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd...
12/02/2025
First Report Managed Care
News
High Health Care Costs Persist for Relapsed/Refractory Multiple Myeloma in the US
11/17/2025
Grace Taylor, MS, MA
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that...
11/17/2025
First Report Managed Care
News
Daratumumab Quadruplet Improves Depth of Response in Older Myeloma
11/10/2025
Hannah Musick
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN...
11/10/2025
First Report Managed Care

Newsfeed

News
Outpatient Cilta-Cel Administration May Reduce Health Care Utilization in RRMM
06/23/2026
Rebecca Amrick
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care...
06/23/2026
First Report Managed Care
News
Talquetamab Shows Lower Cost Per Response in Relapsed or Refractory Multiple Myeloma
06/16/2026
Lisa Kuhns, PhD, MD
Talquetamab delivered more than double the response rate of usual care while lowering the cost per responder, highlighting its potential economic and clinical value for heavily pretreated patients with relapsed or refractory multiple myeloma.
Talquetamab delivered more than double the response rate of usual care while lowering the cost per responder, highlighting its potential economic and clinical value for heavily pretreated patients with relapsed or refractory multiple myeloma.
Talquetamab delivered more than...
06/16/2026
First Report Managed Care
News
Pneumonia Hospitalizations Drive Rising Costs in Multiple Myeloma Care
06/08/2026
Grace Taylor, MS, MA
Pneumonia-related hospitalizations among patients with multiple myeloma are becoming increasingly costly despite declining mortality rates, highlighting persistent disparities and the urgent need for strategies to prevent serious infections...
Pneumonia-related hospitalizations among patients with multiple myeloma are becoming increasingly costly despite declining mortality rates, highlighting persistent disparities and the urgent need for strategies to prevent serious infections...
Pneumonia-related...
06/08/2026
First Report Managed Care
News
Linvoseltamab Demonstrates Lower Care Costs than Teclistamab and Elranatamab for TCE RRMM
05/26/2026
Rebecca Amrick
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower...
05/26/2026
First Report Managed Care
News
Linvoseltamab Demonstrates Improved Efficacy for Patients With TCE RRMM
05/14/2026
Rebecca Amrick
Linvoseltamab outperformed real-world treatment regimens for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM), with higher response rates and more durable outcomes in the LINKER-MM1 trial.
Linvoseltamab outperformed real-world treatment regimens for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM), with higher response rates and more durable outcomes in the LINKER-MM1 trial.
Linvoseltamab outperformed...
05/14/2026
First Report Managed Care
News
Teclistamab Shows Comparable Efficacy but Lower Costs Than Elranatamab in RRMM Study
05/04/2026
Rebecca Amrick
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but...
05/04/2026
First Report Managed Care
News
Real-World Elranatamab in RRMM Falls Short on Durability Despite Strong Initial Responses
04/17/2026
Rebecca Amrick
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising...
04/17/2026
First Report Managed Care
News
Outpatient Cilta-cel Shows Promise in Multiple Myeloma, With Early Signs of Lower Costs and Comparable Outcomes
04/09/2026
Rebecca Amrick
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review...
04/09/2026
First Report Managed Care
News
Higher Health Care Burden in Multiple Myeloma With Extramedullary Disease, Study Finds
12/02/2025
Grace Taylor, MS, MA
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd...
12/02/2025
First Report Managed Care
News
High Health Care Costs Persist for Relapsed/Refractory Multiple Myeloma in the US
11/17/2025
Grace Taylor, MS, MA
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that...
11/17/2025
First Report Managed Care
Behind the Bill
Medicare Cost Cap Act Would Establish Out-of-Pocket Maximum in Traditional Medicare
06/26/2026
Grace Taylor, MS, MA
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would...
06/26/2026
First Report Managed Care
News
Omalizumab Associated With Reduced HCRU and Disease-Related Costs for Food Allergies and Asthma
06/25/2026
Rebecca Amrick
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in...
06/25/2026
First Report Managed Care
News
Social Determinants of Health Negatively Impact Mortality Among Patients With ESKD
06/24/2026
Rebecca Amrick
A systematic review of end-stage kidney disease (ESKD) studies identified multiple health disparities across various domains, highlighting the connection between access barriers and ESKD mortality.
A systematic review of end-stage kidney disease (ESKD) studies identified multiple health disparities across various domains, highlighting the connection between access barriers and ESKD mortality.
A systematic review of end-stage...
06/24/2026
First Report Managed Care
News
Outpatient Cilta-Cel Administration May Reduce Health Care Utilization in RRMM
06/23/2026
Rebecca Amrick
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care...
06/23/2026
First Report Managed Care
News
Impact of Comorbidities on Treatment Patterns and Survival Outcomes in Advanced NSCLC Following ICI Introduction
06/22/2026
Rebecca Amrick
A real-world study found that using immune checkpoint inhibitors (ICIs) to treat non–small cell lung cancer (NSCLC) expanded the use of systemic anticancer treatment (SACT) and significantly increased survival outcomes, even among patients...
A real-world study found that using immune checkpoint inhibitors (ICIs) to treat non–small cell lung cancer (NSCLC) expanded the use of systemic anticancer treatment (SACT) and significantly increased survival outcomes, even among patients...
A real-world study found that...
06/22/2026
First Report Managed Care
News
A Race-Free eGFR Formula Could Improve Care for Patients With Kidney Disease
06/22/2026
Rebecca Amrick
A growing transition to a race-free estimated glomerular filtration rate (eGFR) formula marks a significant step toward more accurate, equitable care for patients with kidney disease, particularly for medication prescription.
A growing transition to a race-free estimated glomerular filtration rate (eGFR) formula marks a significant step toward more accurate, equitable care for patients with kidney disease, particularly for medication prescription.
A growing transition to a...
06/22/2026
First Report Managed Care
Behind the Bill
DOJ and Ohio Attorney General Challenge OhioHealth Managed Care Contracting Practices
06/19/2026
Grace Taylor, MS, MA
Federal and Ohio regulators allege OhioHealth used anticompetitive contracting provisions that limited insurer network design and increased health care costs.
Federal and Ohio regulators allege OhioHealth used anticompetitive contracting provisions that limited insurer network design and increased health care costs.
Federal and Ohio regulators...
06/19/2026
First Report Managed Care
News
Talquetamab Shows Lower Cost Per Response in Relapsed or Refractory Multiple Myeloma
06/16/2026
Lisa Kuhns, PhD, MD
Talquetamab delivered more than double the response rate of usual care while lowering the cost per responder, highlighting its potential economic and clinical value for heavily pretreated patients with relapsed or refractory multiple myeloma.
Talquetamab delivered more than double the response rate of usual care while lowering the cost per responder, highlighting its potential economic and clinical value for heavily pretreated patients with relapsed or refractory multiple myeloma.
Talquetamab delivered more than...
06/16/2026
First Report Managed Care
News
Integrated CKD Care Models Could Improve Early Detection and Outcomes
06/15/2026
Hannah Musick
Population health management strategies that combine early chronic kidney disease (CKD) detection, risk stratification, and integrated primary-nephrology care may help reduce disease progression, cardiovascular complications, and health care...
Population health management strategies that combine early chronic kidney disease (CKD) detection, risk stratification, and integrated primary-nephrology care may help reduce disease progression, cardiovascular complications, and health care...
Population health management...
06/15/2026
First Report Managed Care
Behind the Bill
CMS Tightens Oversight of Medicaid Demonstration Programs and State-Directed Payments
06/12/2026
Grace Taylor, MS, MA
As the Centers for Medicare & Medicaid Services (CMS) intensifies its review of Medicaid demonstration waivers and state-directed payments, managed care stakeholders are assessing what heightened federal scrutiny could mean for program...
As the Centers for Medicare & Medicaid Services (CMS) intensifies its review of Medicaid demonstration waivers and state-directed payments, managed care stakeholders are assessing what heightened federal scrutiny could mean for program...
As the Centers for Medicare &...
06/12/2026
First Report Managed Care

Insights

Jagannath
CONFERENCE COVERAGE
The Path to Cure in Multiple Myeloma: How Emerging Therapies Are Changing the Landscape
10/17/2025
Sundar Jagannath, MBBS
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath,...
10/17/2025
First Report Managed Care
Lonial
CONFERENCE COVERAGE
SOHO 2025 Highlights: Redefining Risk and Treatment in Smoldering Multiple Myeloma
10/10/2025
Sagar Lonial, MD
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his...
10/10/2025
First Report Managed Care
Headshot of Dr Hira Shaikh, University of Iowa
Interview
Hispanic Ethnicity Associated With Worse Multiple Myeloma Outcomes, Study Shows
01/19/2023
Maria Asimopoulos
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant...
01/19/2023
First Report Managed Care
Headshot of Joshua Richter, MD, Mount Sinai
Interview
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Maria Asimopoulos
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate...
10/18/2022
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use